Clinical observation of glutathione to reduce hepatic involvement of statin therapy patients with hepatitis B markers positive
10.3760/cma.j.issn.1008-6706.2012.24.024
- VernacularTitle:还原型谷胱甘肽对他汀类药物致乙型肝炎标志物阳性患者肝损害的预防作用
- Author:
Jianhui RONG
- Publication Type:Journal Article
- Keywords:
Hepatic involvement;
Hepatitis B,chronic;
Glutathione;
Statin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2012;(24):3725-3726
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy of glutathione(GSH)to reduce hepatic involvement of statin therapy patients with hepatitis B markers positive.Methods 164 cases with hepatitis B markers positive were selected and divided into the treatment group(82 cases)and control group(82 cases).In a statin therapy with primary disease,at the same time,the control group using based protect liver therapy(both inosine,vitamin C),the treatment group using reduced glutathione intravenous drip(1.2g,one/d).After 12 weeks,the liver function was examined.Results Patients taking statins ALT,TB and DB levels obviously higher than before,had a statistically significant difference(t=2.66,1.98,2.13,P＜0.05),the differences of observation index level in treatment group before and after treatment had no statistical difference(P＞0.05),12 patients(14.6％)ALT level in treatment group were more than normal,0 case more than normal limit 3 times,control group respectively for 23 cases(28.1％),3 cases(3.7％),two groups had statistically significant difference(x2=4.672,5.304,all P＜0.05).Conclusion GSH can obviously reduce hepatic involvement of statin therapy patients with hepatitis B markers positive.
